Helena Yu

38PUBLICATIONS

424CO-AUTHORS

Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyAnalytical spectrometry

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (38)

Sort by Publication Date:

|Jul 14, 2026

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

|Jul 13, 2026

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|Jun 17, 2026

Clinicogenomic analysis of <i>EGFR</i>-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation.

|May 14, 2026

Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non-Small Cell Lung Cancer.

|Mar 06, 2026

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.

Helena A Yu, Kwan Ho Tang, Aleksandra A Markovets

|Dec 30, 2025

TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i>-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib.

Daniel Shao-Weng Tan, Ernest Nadal, Parneet Cheema

Pageof 7

Frequent Collaborators

11 joint publications

Charles M Rudin

Zofia Piotrowska

Marc Ladanyi

Pasi A Jänne

Michael Offin

Alexander Drilon

Gregory J Riely

Jorge S Reis-Filho

James Chih-Hsin Yang

Byoung Chul Cho

Frequent Collaborators

11 joint publications

Charles M Rudin

7 joint publications

Zofia Piotrowska

6 joint publications

Marc Ladanyi

4 joint publications

Pasi A Jänne